Did you know that Premature Ejaculation (PE) is the most common male sexual dysfunction worldwide? Millions of men around the world suffer from this debilitating drawback and yet even today it remains one of the most poorly understood phenomena in the medical world. Experts in PE from the International Society of Sexual Medicine (ISSM) define the condition as consisting of three major components: a short time to ejaculation (prior to…
Lexapro (Escitalopram) has been shown to be of benefit in some stroke patients. Read on…Antidepressants may help stroke victims - Los Angeles Times
Crestor has been approved by the FDA to fight heart disease in people who would not normally recieve a cholesterol lowering drug. Read on..Crestor Approved to Fight More Heart Disease
Read about how non-prescription Heliocare offers sun protection in a pill. Read on..Sun protection in a pill?
A twice-daily dose of Celebrex over a period of nine months reduced the incidence of nonmelanoma skin cancer by almost 60 percent, according a new study. Read on..SID: COX-2 Inhibitors May Cut Skin Cancer Rate
Statin drugs, a commonly prescribed class of lipid-lowering drugs that include Lipitor, Zocor and Crestor, do not prevent Alzheimer’s disease or dementia, according to a report in the Cochrane Database of Systematic Reviews. Read on..Statin drugs do not prevent dementia
Some of the best-selling drugs, including Lipitor, Plavix, Avapro, Zyprexa, Effexor, Cozaar/Hyzaar and Singulair will be exposed to generic competition between now and 2012. S&P Ratings compiles its list of the most promising late-stage drugs due out over the next two years.Read On..Pharma: The 10 Most Promising New Drugs
Recently released data has showed that Eli Lilly’s Cialis may be effective in relieving lower urinary tract symptoms caused by benign prostatic hyperplasia in men. Read on..Cialis Helps the Prostate
Cialis, in a lower dose form, has been approved for long-term daily use for erectile dysfunction (ED). Read on..Once-daily Cialis makes any time the right time
Tricyclic anti-depressants such as Elavil, selective serotonin reuptake inhibitors (SSRIs) such as Prozac or Lexapro, and especially serotonin and norepinephrine reuptake inhibitors (SNRIs) such as Effexor or Cymbalta, which are dual-acting antidepressants that can increase both serotonin and norepinephrine, have proven capable of decreasing pain while treating both depression and chronic pain. Because pain can induce depression and vice versa, these new dual-acting agents can provide physicians with safe and…